GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, have entered into an exclusive worldwide collaboration for the development and commercialisation of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD).
Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau
- Details
- Category: Pfizer
Pfizer Inc (NYSE:PFE) has announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Wyeth. In addition, Pfizer has received approval from the Canadian Competition Bureau for the pending acquisition.
Expert Panel Offers Three-Step Plan to Guide People Toward Recovery of Depression
- Details
- Category: Eli Lilly and Company
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well.(1)
Abbott Reports 16.5 Percent Earnings Growth in Third Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009. "Abbott is performing well, generating higher-than-expected earnings growth in the third quarter," said Miles D. White, chairman and chief executive officer, Abbott.
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM)
- Details
- Category: Novartis
Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in early 2010.
GSK's Avodart® / tamsulosin combination showed benefits for men with prostate enlargement
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that final results from a large, 4-year study showed that Avodart (dutasteride) and tamsulosin combination treatment reduced the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia* (BPH)-related surgery and reduced the risk of BPH clinical progression more than tamsulosin alone**.
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
- Details
- Category: Business
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has signed a definitive agreement to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
More Pharma News ...
- FDA Advisory Committee Recommends Approval of Pfizer's Selzentry
- Access to HIV medication
- GSK expands presence in China through strategic cooperation
- Sandoz launches somatropin, the first-ever Japanese biosimilar
- Takeda to Establish Four Sales and Marketing Subsidiaries
- Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
- Merck Submits Application for Cladribine Tablets